Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Remington

Showing results (41-50 of 410) with videos related to

Pageof 41
Sort By:
Focus (American Psychiatric Publishing)|November 20, 2024
Renal Impairment and Dose Adjustment of Long-Acting Injectable Antipsychotics: Are We Getting It Right? A Case ReportColette Raphaël, Gary Remington, Ofer Agid
Schizophrenia Research|December 20, 2005
Validation of a physical activity assessment tool for individuals with schizophreniaGuy Faulkner, Tony Cohn, Gary Remington
Journal of Clinical Psychopharmacology|September 15, 2016
Incidence of Antipsychotic-Associated Side Effects: Impact of Clinician Versus Patient Ratings and Change Versus Absolute ScoresHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Journal of Clinical Psychopharmacology|October 20, 2015
Effect of Antipsychotic Dosing Regimen on Neurocognition in SchizophreniaHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Journal of Clinical Psychopharmacology|June 23, 2004
Tardive dyskinesia and iron statusSiow-Ann Chong, Mythily, Gary Remington
Schizophrenia Bulletin|April 24, 2007
Interventions to reduce weight gain in schizophreniaGuy Faulkner, Tony Cohn, Gary Remington
Expert Opinion on Pharmacotherapy|July 1, 2010
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse preventionOfer Agid, George Foussias, Gary Remington
Journal of Clinical Psychopharmacology|May 31, 2014
Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfallsJimmy Lee, Hiroyoshi Takeuchi, Gary Remington
Expert Opinion on Emerging Drugs|September 4, 2008
Emerging drugs for schizophreniaOfer Agid, Shitij Kapur, Gary Remington
Psychiatry Research|August 21, 2016
Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratingsHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Pageof 41

Showing results (41-50 of 410) with videos related to

Sort By:
Pageof 41
Focus (American Psychiatric Publishing)|November 20, 2024
Renal Impairment and Dose Adjustment of Long-Acting Injectable Antipsychotics: Are We Getting It Right? A Case ReportColette Raphaël, Gary Remington, Ofer Agid
Schizophrenia Research|December 20, 2005
Validation of a physical activity assessment tool for individuals with schizophreniaGuy Faulkner, Tony Cohn, Gary Remington
Journal of Clinical Psychopharmacology|September 15, 2016
Incidence of Antipsychotic-Associated Side Effects: Impact of Clinician Versus Patient Ratings and Change Versus Absolute ScoresHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Journal of Clinical Psychopharmacology|October 20, 2015
Effect of Antipsychotic Dosing Regimen on Neurocognition in SchizophreniaHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Journal of Clinical Psychopharmacology|June 23, 2004
Tardive dyskinesia and iron statusSiow-Ann Chong, Mythily, Gary Remington
Schizophrenia Bulletin|April 24, 2007
Interventions to reduce weight gain in schizophreniaGuy Faulkner, Tony Cohn, Gary Remington
Expert Opinion on Pharmacotherapy|July 1, 2010
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse preventionOfer Agid, George Foussias, Gary Remington
Journal of Clinical Psychopharmacology|May 31, 2014
Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfallsJimmy Lee, Hiroyoshi Takeuchi, Gary Remington
Expert Opinion on Emerging Drugs|September 4, 2008
Emerging drugs for schizophreniaOfer Agid, Shitij Kapur, Gary Remington
Psychiatry Research|August 21, 2016
Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratingsHiroyoshi Takeuchi, Gagan Fervaha, Gary Remington
Pageof 41